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Abstract
Preventing utilization of hospital and emergency department after diagnosis of venous thromboembolism is a complex 
problem. The objective of this study is to assess the impact of a care transition intervention on hospitalizations and 
emergency department visits after venous thromboembolism. We randomized adults diagnosed with a new episode of 
venous thromboembolism to usual care or a multicomponent intervention that included a home pharmacist visit in the 
week after randomization (typically occurring at time of discharge), illustrated medication instructions distributed during 
home visit, and a follow-up phone call with an anticoagulation expert scheduled for 8 to 30 days from time of randomization. 
Through physician chart review of the 90 days following randomization, we measured the incidence rate of hospital and 
emergency department visits for each group and their ratio. We also determined which visits were related to recurrent 
venous thromboembolism, bleeding, or anticoagulation and which where preventable. We enrolled 77 intervention and 85 
control patients. The incidence rate was 4.50 versus 6.01 visits per 1000 patient days in the intervention versus control 
group (incidence rate ratio = 0.71; 95% confidence interval = 0.40-1.27). Most visits in the control group were not related 
to venous thromboembolism or bleeding (21%) and of those that were, most were not preventable (25%). The adjusted 
incidence rate ratio for the intervention was 1.05 (95% confidence interval = 0.57-1.91). Our patients had a significant 
number of hospital and emergency department visits after diagnosis. Most visits were not related to recurrent venous 
thromboembolism or bleeding and of those that were, most were not preventable. Our multicomponent intervention did 
not decrease hospitalizations and emergency department visits.
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Original Research
What do we already know about this topic?
Hospitalization and emergency department (ED) visits following an initial case of venous thromboembolism (VTE) 
comprise a significant health burden.
How does your research contribute to the field?
A multicomponent intervention including pharmacist home visit, illustrated medication instructions, and subsequent 
telephone consultation with an anticoagulation expert does not appear to be sufficient to reduce hospital and ED visits 
related to VTE.
What are your research’s implications toward theory, practice, or policy?
To reduce utilization of hospital and ED after VTE diagnosis, future interventions should address comorbid health prob-
lems and support patients more broadly than providing education around VTE and anticoagulation.




Venous thromboembolism (VTE) comprising deep vein 
thrombosis (DVT) and pulmonary embolism (PE) is the 
cause of significant health burden in the United States. The 
annual incidence of VTE is 900 000 and the cost of treating 
these cases totals approximately $10 billion.1 Utilization of 
hospital or emergency department (ED) after initial case of 
VTE is an important part of this burden. The frequency of 
this utilization after hospitalization for VTE has been esti-
mated in 1 report to equal 20%.1 Although other cardiopul-
monary conditions such as congestive heart failure and 
myocardial infarction have been the primary focus of payer 
efforts in terms of preventing readmissions, VTE would 
appear to be another prime target for quality improvement 
and cost containment efforts.2
Preventing utilization of hospital and ED after diagnosis 
of VTE is a complex problem. Patients typically start on an 
anticoagulant in cases of initial VTE or resume taking an 
anticoagulant at a new dose or with new instructions in the 
case of recurrent VTE. Many issues may complicate initia-
tion and maintenance of anticoagulation thereafter. Patients 
may have trouble obtaining anticoagulant medication. The 
prescribed anticoagulant can interact with other medications 
or conflict with patient diets. In addition, patients may not 
appreciate the importance of strict adherence with anticoagu-
lation or have the knowledge of which symptoms to report as 
demonstrated previously.3 Each of these scenarios could lead 
to recurrent VTE or major bleeding, which in turn will result 
in hospitalization or an ED visit. In addition, patients with 
VTE frequently have other underlying conditions particu-
larly malignancy (ie, malignancy-associated VTE) or have 
undergone recent surgery (ie, provoked VTE).1,4
The various scenarios that could lead to hospitalizations 
and ED visits suggest the need for a comprehensive, multi-
component intervention. A prominent, previous study enroll-
ing patients admitted with cardiac problems did not see a 
reduction in utilization for a care transition intervention 
including medication reconciliation by a pharmacist at the 
time of discharge, illustrated medication instructions, and 
telephone consultation with a pharmacist in the days after 
discharge.5 To have more impact whether for cardiac disease 
or VTE likely requires a more intensive intervention that 
goes beyond telephonic pharmacist consultation and one that 
goes beyond the immediate postdischarge period. To our 
knowledge, there is no prior study that has rigorously evalu-
ated the effectiveness of a multicomponent, pharmacist-
based care transition intervention that we hypothesized 
would be necessary for reducing utilization after diagnosis 
for patients with VTE.
We recently reported the findings of a multicomponent 
intervention including home pharmacist visit scheduled 
shortly after diagnosis, illustrated medication instructions, 
and follow-up phone call with an anticoagulation expert 
weeks after diagnosis for patients with VTE.6 Of note, we did 
not find a significant effect on interview-based outcomes 
including quality of care transition as per the Care Transition 
Measure-15 collected 30 days after randomization,7 patient 
knowledge of anticoagulation and VTE, and patient antico-
agulation beliefs and a proxy for adherence. In this article, 
we focus on the utilization of hospitalizations and ED visits 
for the same trial patients.
Methods
Population
We included English-speaking adults aged 18 and older with 
an episode of VTE diagnosed in the previous 2 weeks in hos-
pital or ambulatory settings (office or ED) and prescribed 
warfarin, direct oral anticoagulant, or low molecular weight 
heparin. We excluded patients being discharged to a nursing 
home.
Setting
We conducted this study within the UMass Memorial Health 
Care (UMMHC) system, a multihospital health care system 
in central Massachusetts. The University of Massachusetts 
Medical School (UMMS) Institutional Review Board (IRB) 
reviewed and approved this study.
Procedure
Recruitment and randomization. We screened radiology 
reports daily for new cases of VTE. We then approached 
patients either in person, during the encounter in which the 
patient received VTE diagnosis, or up to 2 weeks afterwards 
1University of Massachusetts Medical School, Worcester, USA
2University of Massachusetts Memorial Health Care, Worcester, USA
3Massachusetts College of Pharmacy and Health Sciences, Worcester, USA
4University of Massachusetts Memorial Medical Center, Worcester, USA
5HealthAlliance-Clinton Hospital, Leominster, MA, USA
6Beth Israel Deaconess Medical Center, Boston, MA, USA
Received 17 November 2019; revised manuscript accepted 22 November 2019
Corresponding Author:
Alok Kapoor, The Meyers Primary Care Institute, University of Massachusetts Medical School, 365 Plantation Street, Worcester, MA 01605, USA. 
Email: alok.kapoor@umassmemorial.org
Kapoor et al 3
by telephone. In the latter case, we obtained verbal consent 
followed by written consent requested via mail. Following 
recruitment and interview for baseline information, we ran-
domized enrolled patients to either intervention or control 
using the randomization module within Research Electronic 
Data Capture (REDCap).8
Intervention patients. Our intervention consisted of 3 key 
components listed below. We did not provide other medica-
tion management services such as international normalized 
ratio (INR) or other lab monitoring and deferred to the pri-
mary care provider (PCP) to arrange them. To ensure stan-
dardization of the home visit, we composed a manual for the 
conduct of home visits (manual available upon request of the 
authorship team). For each pharmacist who conducted home 
visits, the principal investigator (PI; AK) accompanied the 
pharmacist for a minimum of 2 visits prior to allowing phar-
macist to conduct unsupervised visits:
1. Home visit. The home visit occurred within 7 days of 
randomization. During the home visit, the pharmacist 
conducted a medication self-management simulation 
that builds on the “show me”/teach back paradigm 
advocated by experts.9 This followed a protocol we 
previously validated.10 Briefly, we requested that the 
patients collect all of their medications and pill orga-
nizers. We then asked patients to sequentially iden-
tify each of their medications on their medication list, 
explain the reason for taking each medication, and 
indicate/demonstrate how and with what frequency 
to take each medication. Although the primary focus 
of our intervention was to support use of anticoagula-
tion, the pharmacist reviewed up to 9 other medica-
tions during the simulation and remediated any 
errors. Next, the pharmacist asked a series of open-
ended questions to gauge each patient’s knowledge 
of VTE, anticoagulation, drug interactions, symp-
toms to report, and dietary restrictions. Although our 
team internally discussed and reviewed individual 
cases with our pharmacist and strategized about how 
best to educate patients, we did not provide patients a 
set of fixed materials/handouts but rather relied on 
the discretion and judgment of the individual phar-
macist including for advising patients what to do in 
the event of acute bleeding episodes. The combina-
tion of remediation during the simulation filling in 
gaps in knowledge during the open-ended questions 
section, and review of illustrated medication instruc-
tions constituted the education provided by the phar-
macist during home visits (see Supplemental 
Appendix A for data collection form).
2. Illustrated medication instructions. Near the end of 
the home visit, the pharmacist reconciled the patient’s 
medications and printed illustrated medication 
instructions on a mobile color printer using PictureRx, 
an educational aid developed by the authors of the 
previously mentioned care transition intervention 
study.5 The Web-based software uses icons to aid 
patients in understanding the purpose and dosing 
schedule of their medications.
3. Anticoagulation expert telephone consultation. Be -
tween 8 and 30 days from the time of randomization, 
our anticoagulation expert, a nurse practitioner work-
ing in the UMMHC Anticoagulation Clinic, con-
tacted each intervention patient via telephone. The 
nurse practitioner’s credentials include MS, NP-BC, 
and CACP (Certified Anticoagulation Care Provider). 
During the telephone call, the anticoagulation expert 
used the same open-ended format discussed above to 
gauge and remediate patient knowledge. She also 
reconciled meds and sent the patient a color copy of 
the illustrated medication instructions if there were 
any changes in medications since the time of the 
home visit or if the patient did not complete the home 
visit (see Figure 1 for illustration of intervention 
timeline)
Figure 1. Study intervention and data collection flow diagram.
Note. We recruited patients’ N days after VTE diagnosis; we permitted up to 14 days for N. We scheduled the home visit in the first 7 days and the 
expert phone call between 8 and 30 days after randomization. VTE = venoushromboembolism; ED = emergency department.
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Control patients. Control patients received standard dis-
charge paperwork (without illustrated medication instruc-
tions) from hospital or ED. At the time of our study, our 
health system used Siemens Soarian Clinicals electronic 
medical record in the hospital11 and ED PulseCheck in the 
emergency room.12 Items in patient discharge instructions 
included reason and main diagnosis for visit, follow-up 
instructions and appointments, diet to observe, and instruc-
tions for returning to institution, for example, fever, short-
ness of breath and so on. Control patients did not have any 
contact with our intervention pharmacist or anticoagulation 
expert.
Outcome
Our outcome was the count of hospitalizations and ED visits 
identified through both chart review of our electronic medi-
cal record (EMR) and telephone calls to patients conducted 
90 days after randomization. We selected 90 days to include 
the period over which many patients (ie, those with provoked 
VTE) complete anticoagulation.
Chart review with blinded outcome adjudication. Physicians 
from our team (SJ, RE, AN, AM, or XC) reviewed the EMR 
for each patient to identify hospitalization or ED visit occur-
ring up to 90 days after randomization. Prior to reviewing 
charts unsupervised, the PI (AK) reviewed charts in dupli-
cate in batches of 5. Once the reviewer developed sufficient 
proficiency that there were no major discrepancies between 
his/her review and the PI, the reviewer continued reviewing 
charts unsupervised. To capture events occurring outside of 
our health system, our reviewers also examined progress 
notes and telephone encounters in our EMR for information 
about external utilization. We did not collect documentation 
from external facilities. To blind reviewers to patient treat-
ment allocation, we created customized logins for them 
which prevented access to documentation made by the phar-
macist or anticoagulation expert:
Further characterization of visits using chart review. For each 
hospitalization or ED visit identified, we recorded several 
variables. These included whether the visit related to VTE, 
bleeding, or anticoagulation (i.e. the index condition) includ-
ing any related symptoms or recurrence. If the visit was 
related to the index condition, the reviewer also recorded 
whether he or she felt the visit was preventable with better 
adherence with anticoagulant, better control of anticoagu-
lant, avoidance of another medication that could have inter-
fered with anticoagulant, or better education of the patient 
about what to expect (e.g. minor bleeding while brushing 
teeth). If not related to VTE, bleeding, or anticoagulation, 
we documented an alternate reason for the visit. For each 
patient, we recorded up to 3 visits given the clinical experi-
ence of our authors that patients would not typically utilize 
more than 3 visits.
Follow-up interview. We called and asked patients whether 
they were hospitalized or went to the ED outside of our 
health system within the 90 days following randomization 
into our study. If either had occurred, we asked when and 
where they occurred and inquired about the reason for the 
visit.
Covariates
We identified demographic and clinical factors associated 
with utilization and readmission in general and after VTE 
diagnosis in particular. We selected these factors based on 
clinical expertise of our authors as well as previous stud-
ies.1,13,14 (see Table 1 for full listing)
Time observed
For each patient, we assessed the length of follow-up (which 
we refer to as “time observed”) over the 90 days following 
randomization. Specifically, during chart review, our physi-
cian reviewers recorded the last day that the patient accessed 
care within our health system. If the last day of follow-up 
occurred on or before the date of randomization, we assigned 
a nominal time observed of 0.5 days consistent with the prac-
tice of other longitudinal studies.15-17 For patients with less 
than 90-day follow-up within our health system, we accepted 
information reported during 90-day interviews about hospi-
talizations and ED visits occurring externally. We illustrate 
this and all other scenarios in Figure 2.
Analysis
First, we examined the distribution of the covariates for 
intervention versus control patients. We then measured the 
incidence rate of hospitalization and ED visits in each group. 
For our calculations, we calculated incidence rate as the 
number of events divided by the sum of time observed in 
each group.
To assess the independent effect of our intervention on 
hospitalization and ED visits, we constructed a multivariate 
model that included covariates as well as the group assign-
ment and time observed for each patient. Given that more 
than 70% of patients in our study did not have any hospital-
ization or ED visits, we chose a negative binomial distribu-
tion to fit our data. In order to establish a parsimonious 
model, we entered all covariates mentioned above in our 
equation and then selectively removed those that did not 
change the effect of our intervention. Given small numbers, 
we did not specifically examine the effect of patient perfor-
mance in the medication management simulation or other 
parts of our intervention.
Because several patients assigned to the intervention did 
not complete 1 or more of the components of our interven-
tion, we conducted 2 sets of analyses. The first included those 
patients not completing all parts of the interventions—that is, 
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Table 1. Comparison of Demographic and Clinical Factors for Patients With Venous Thromboembolism Assigned to Multicomponent 
Care Transition Intervention Versus Controls.
Demographic and clinical factors
Intervention patients Control patients
P value
Frequency  
(% out of 77 total)
Frequency  
(% out of 85 total)
Gender
 Female 32 (41.6) 38 (44.7) .69
 Male 45 (58.4) 47 (55.3)
Racial background
 White 68 (88.3) 64 (75.2) .18
 Black 4 (5.2) 7 (8.2)
 Asian/Pacific Islander/Native American/Alaskan/More than 1 race 2 (2.6) 6 (7.1)
 Don’t know/Prefer not to answer/Missing 3 (3.9) 8 (9.4)
Ethnicity
 Hispanic 2 (2.6) 9 (10.6) .09
 Not Hispanic 73 (94.8) 72 (84.7)
 Don’t know/Prefer not to answer/Missing 2 (2.6) 4 (1.2)
Income level
 ≤100% poverty level 8 (10.4) 5 (5.9) .3
 100%-400% poverty level 19 (24.7) 15 (17.7)
 >400% poverty level 23 (29.9) 24 (28.2)
 Don’t know/Prefer not to answer/Missing 27 (35.1) 41 (48.2)
Education
 High school or below 21 (27.3) 18 (21.2) .54
 Above high school 54 (70.1) 63 (74.1)
 Missing 2 (2.6) 4 (4.7)
Health literacy: confidence filling out medical forms
 Inadequate (Somewhat/A little bit/Not at all) 21 (27.3) 17 (20.0) .46
 Adequate (Extremely/Quite a bit) 54 (70.1) 64 (75.3)
 Missing (Don’t know/Prefer not to answer) 2 (2.6) 4 (4.7)
Patient activation: PAM-13 score
 1. Disengaged and overwhelmed 4 (5.2) 8 (9.4) .44
 2. Becoming aware, but still struggling 11 (14.5) 18 (21.2)
 3. Taking action 31 (40.8) 28 (32.9)
 4. Maintaining behaviors and pushing further 30 (39.5) 31 (36.5)
Charlson Comorbidity Index
 0 35 (45.5) 29 (34.1) .03
 1 21 (27.3) 17 (20.0)
 2 8 (10.4) 23 (27.1)
 3+ 13 (16.9) 16 (18.8)
VTE type
 DVT alone 40 (52.0) 33 (38.8) .25
 PE 24 (31.2) 34 (40.0)
 Both 13 (16.9) 18 (21.2)
VTE etiology
 Provoked VTE 28 (36.4) 35 (41.2) .92
 Cancer associated 9 (11.7) 10 (11.8)
 Unprovoked VTE 31 (40.3) 30 (35.3)
 Unclear/Unable to determine/Missing 9 (11.7) 10 (11.8)
Anticoagulant prescribed
 Warfarin 37 (48.1) 39 (45.9) .92
 Direct oral anticoagulant 29 (37.7) 32 (37.7)
 Enoxaparin 11 (14.3) 14 (16.5)
Care transition type
 Hospital to home 48 (62.3) 59 (69.4) .49
 ED to home 15 (19.5) 16 (18.8)
 Ambulatory to home 14 (18.2) 10 (11.8)
Note. PAM = patient activation measure; DVT = deep venous thrombosis; PE = pulmonary embolism; VTE = venous thromboembolism; ED = 
emergency department.
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“intention-to-treat (ITT) cohort.” The second included only 
“completers.”
Although we did not assess the power of our study design 
to detect a difference in hospitalizations or ED visits a priori, 
we estimated, post hoc, the range of statistical power our 
study had to detect, a 5% to 50% decrease in the use of hos-
pital and ED. We performed all calculations in Statistical 
Analysis Software (SAS) 9.4.18
Figure 2. Determination of time observed for incidence rate calculation in 4 different scenarios.
Note. VTE = venous thromboembolism; ED = emergency department; ITT = intention to treat.
*Number in parentheses represents the number of patients from ITT cohort which fit with this scenario. **We recruited patients N days after VTE 
diagnosis; we permitted up to 14 days for N.
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Results
ITT cohort
Of the 415 eligible patients, 194 verbally consented to par-
ticipate in the study and were still eligible at the time of ran-
domization. As we also required written consent and many 
patients did not return written consent documents to us, our 
fully consented, ITT cohort included 162 patients: 77 inter-
vention patients and 85 controls (Figure 3). This cohort was 
mostly white with a high school or higher level education. 
There were no significant differences between intervention 
and control patients for most variables apart from the 
Charlson comorbidity Index which was lower in intervention 
patients (P = .03). Approximately two thirds of our popula-
tion had a transition from hospital to home. Transition from 
hospital to home included cases of DVT or PE developing 
during admission or cases of DVT or PE requiring hospital-
ization after diagnosis in the ambulatory setting (Table 1).
Figure 3. CONSORT diagram of patients included in study recruitment, randomization, and analysis.
Note. *Fully consented represent those individuals consented in person and providing written consent from the outset and those consented by telephone 
and having returned written consent within 50 days of randomization.
8 INQUIRY
Combined population information. In the 90 days after ran-
domization, the combined population of intervention and 
control patients had 34 hospitalizations and 29 visits to the 
ED for a total of 63 encounters. Of the 63 encounters, 25 
(39.7%) occurred in the first 30 days affecting 19 of 162 
patients (11.7%). Overall, 46 patients (28.4%) had at least 1 
encounter with 33 patients (20.4%) having exactly 1 encoun-
ter, 6 patients (3.7%) having 2 encounters, and 5 patients 
(3.1%) having 3 encounters.
Comparison of visits in intervention versus controls. There were 
differences in the frequency and type of hospitalizations/ED 
visits utilized by intervention versus control patients. Inter-
vention patients had significantly fewer total visits compared 
with controls (25 vs 38). Of the 25 visits in intervention 
patients, 14 (56.0%) were related to VTE, bleeding, or anti-
coagulation compared with only 7 (18.4%) of 38 total visits 
for controls. Other causes of hospital or ED utilization 
included upper respiratory tract diseases, musculoskeletal 
pain complaints, and neurologic events (eg, stroke, seizure; 
Supplemental Appendix B). Of the visits related to VTE, 
bleeding, or anticoagulation, only 5 intervention group visits 
were preventable and only 2 control visits were preventable 
(Table 2).
Time observed. We observed intervention patients for a total 
of 5778 days and controls for a total of 6320 days. In Figure 
3, we list the number of patients falling into each of 4 sce-
narios relating to the determination of time observed.
Incidence rate. The incidence rate was 4.50 visits per 1000 
patient days in the intervention group and 6.01 visits per 
1000 patient days in the controls. Using the negative bino-
mial model including only treatment assignment and time 
observed, we found that the incidence rate ratio (IRR) of uti-
lization for the intervention was 0.71 (95% confidence inter-
val [CI] = 0.40-1.27). After adjusting for covariates of a 
parsimonious model, the IRR was no different between 
groups (IRR =1.05; 95% CI = 0.57-1.91), which corre-
sponded to a power of 5% to 98% to detect a 5% to 50% 
Table 2. Frequency of Hospitalizations and ED Visits and Descriptive Information About Visits in Intention-to-Treat Cohort.
Intervention frequency  
(% total intervention visits)
Control frequency  
(% total control visits) P value*
Hospitalizations 11 (44.0) 23 (60.5) .05
Related to VTE, bleeding, or anticoagulation 6 (24.0) 3 (7.9)  
Reason for visit
 Recurrent VTE 0 (0.0) 0 (0.0)  
 Bleeding—major or nonmajor clinically relevant 1 (4.0) 2 (5.3)  
  Other (eg, shortness of breath, suspicion of new VTE not  
 confirmed, minor bleeding)
5 (20.0) 1 (2.6)  
Preventablea 2 (8.0) 2 (5.3)  
Not preventable 4 (16.0) 1 (2.6)  
Not related to VTE, bleeding or anticoagulation 5 (20.0) 20 (52.6)  
ED visits 14 (56.0) 15 (39.5) .93
Related VTE, bleeding, or anticoagulation 8 (32.0) 4 (10.5)  
Reason for visit
 Recurrent VTE 0 (0.0) 0 (0.0)  
 Bleeding—major or nonmajor clinically relevant 4 (16.0) 0 (0.0)  
  Other (eg, shortness of breath, suspicion of new VTE not  
 confirmed, minor bleeding)
4 (16.0) 4 (10.5)  
Preventablea 3 (12.0) 0 (0.0)  
Not preventable 5 (20.0) 4 (10.5)  
Not related to VTE, bleeding, or anticoagulation 6 (24.0) 11 (28.9)  
Total number of visits 25 38 .11
Total number of days patients in group observed 5778 6320  
Incidence rate (per 1000 patient days followed) 4.33 6.01  
Incidence rate ratio (intervention compared with controls)b 0.71 (95% CI = 0.40-1.27)  
Note. There were 77 patients in the intervention group and 85 in the control group. VTE = venous thromboembolism; ED = emergency department; CI 
= confidence interval.
aWe asked reviewers to mark preventable if visit would have been preventable with better adherence with medication, better control of anticoagulant, 
avoidance of another medication that could have interfered with anticoagulant, or better education of the patient about what to expect (minor bleeding 
while brushing teeth, etc).
bIn the table, we cite the unadjusted incident rate ratio; in the body of the article, we describe the process of controlling for confounding which resulted 
in an adjusted incident rate ratio 1.05 (95% CI = 0.57-1.91).
*P value calculated with chi-square test.
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reduction in the incidence rate (with 80% power to detect a 
40%-50% reduction in incidence rate). The parsimonious 
model included gender, income, race, Hispanic ethnicity, 
blood clot type, health literacy, patient activation, and Charl-
son score.
Completers
There were 139 patients in this cohort: 54 intervention 
patients and the same 85 controls. Intervention patients in this 
cohort were much more likely to be white and non-Hispanic 
compared with controls (P = .02 and .01, respectively).
In terms of hospitalizations and ED visits, we saw a simi-
lar pattern as in the ITT cohort with 17 total visits for inter-
vention patients compared with 38 for controls. The 
difference in the incidence rate was larger in this cohort with 
4.07 versus 6.01 visits per 1000 patient days for intervention 
versus controls patients (Supplemental Appendix C). After 
adjusting for covariates, we found the IRR for intervention 
cohort was 1.23 (95% CI = 0.61-2.46).
Conclusion and Relevance
We found that a significant number of visits to hospital and 
ED occur in the 90 days after diagnosis of VTE. Our multi-
component intervention was associated with a reduction of 
hospitalizations and ED visits but most of the excess visits in 
the control group were not related to VTE, bleeding, or anti-
coagulation. After adjustment for demographic and clinical 
factors, there was no difference in utilization between the 
groups.
Our study finding of a high rate of utilization occurring 
after VTE diagnosis is consistent with other published 
reports. Secemsky et al found that 17.5% of patients had 
readmission to hospital within 30 days of VTE hospitaliza-
tion.1 They did not measure utilization of ED, calculate an 
incidence rate, or follow up patients out to 90 days limiting 
comparison with our study. We did not have sufficient sam-
ple size to examine the distinct effect of the intervention in 
low health literacy patients.
The major implication of our findings is that our compos-
ite intervention was not associated with a decrease in hospi-
talizations or ED visits. Another major implication of our 
findings is that preventing utilization of hospital and ED 
after diagnosis of VTE likely requires more than education 
around VTE. Most of the hospitalizations and visits to the 
ED we recorded were not related to VTE, bleeding, or anti-
coagulation. Patients with VTE have significant other comor-
bidities and medication issues which drive utilization.1 
Moreover, although we anticipated utilization would track 
with quality of care transition as measured through the Care 
Transition Measure-15 (our primary outcome described in 
our previous article),6 we did not explicitly design our inter-
ventions to reduce utilization. Although we conducted medi-
cation reconciliation and medication simulation during home 
visits, we did not provide significant education related to 
medications other than anticoagulants. Another avenue of 
future research may shift from an intervention focused on 
education to one focused on care coordination or patient 
coaching. The Care Transition Intervention developed by 
Eric Coleman and others found that pairing patients with a 
nurse transition coach reduced 90-day readmission rates by 
25%.19 The Care Transition Intervention study included older 
adults hospitalized for a variety of conditions. It is unclear 
whether a transition coach can also reduce utilization after 
diagnosis for VTE in adults of any age.
We acknowledge a limitation to the findings we report. A 
significant number of patients assigned to the intervention 
did not receive all parts of it. If we had more patients com-
pleting all parts of the intervention, we may have prevented 
additional hospitalizations related to recurrent VTE, bleed-
ing, or anticoagulation. Nevertheless, we did not see a sig-
nificant effect of our intervention in the completers cohort 
confirming the overall conclusion that it did not reduce 
90-day utilization. The relatively small size of our study pop-
ulation limited our ability to find an effect size of less than 
40% for our intervention, if it existed. We also caution that 
we did not assess our statistical power a priori and post hoc 
power calculations are controversial.20 The sample size 
available also limited the ability to examine the effect of our 
intervention in subpopulations such as those with inadequate 
health literacy. We also did not have the sample size to look 
at discrete utilization of hospital versus ED.
In conclusion, we found that patients have a significant 
number of hospital and ED visits after VTE diagnosis. The 
composite intervention of a home pharmacist visit, illus-
trated medication instructions, and subsequent telephone 
consultation with an anticoagulation expert did not reduce 
visits related to recurrent VTE, bleeding, or anticoagulation. 
Future research should focus on testing other interventions 
for patients with VTE.
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